Claims of US Patent No. 8,927,705 Cover Composition of Matter of Dicerna's Next-Generation Proprietary Payloads for RNAi Therapeutics and Self-Targeting Conjugates
The patent provides broad composition of matter claims that describe double-stranded RNA (dsRNA) molecules, called extended Dicer substrate short interfering RNAs (DsiRNA-EX), possessing single-stranded extensions of variable length on their 5' and/or 3' ends. The single-stranded features provide multiple functional attributes, enhancing the therapeutic potential of these DsiRNA-EX molecules and improving their chemical and biological properties. Notably, the extensions enable the development of subcutaneously delivered molecules that are self-targeting and possess enhanced biological stability. These and other favorable features are introduced into the dsRNA while the molecules nonetheless maintain extremely high RNAi activity. This issued patent complements previously issued US Patent No. 8,349,809, which describes the methods of use of such extension-containing dsRNA molecules. Dicerna will identify this RNAi platform as its DsiRNA-EX platform.
"These composition claims further expand the issued Dicerna patent
portfolio and reinforce our unique position in the RNAi space," said
Several of Dicerna's development programs already employ the DsiRNA-EX technology, which supports self-delivering molecules that can be administered both subcutaneously and by intravenous injection, as clinical circumstances dictate.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Applicable risks and uncertainties include
those relating to our preclinical research and other risks identified
under the heading "Risk Factors" included in our most recent Form 10-Q
filing and in other future filings with the
News Provided by Acquire Media